Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021)

Journal of Virology

Volumn 79, Issue 15, 2005, Pages 9572-9578

  Delaunay, Christophe ^a   Brun Vézinet, Françoise ^a   Landman, Roland ^a   Collin, Gilles ^a   Peytavin, Gilles ^a   Trylesinski, Aldo ^b   Flandre, Philippe ^c   Miller, Michael ^d   Descamps, Diane ^a  

^a BICHAT HOSPITAL   (France)

^b Gilead Sciences   (France)

^c HÔPITAL PAUL BROUSSE   (France)

^d GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; LAMIVUDINE; NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE; TENOFOVIR; VIRUS RNA;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG POTENCY; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MOLECULAR CLONING; PHYLOGENY; PILOT STUDY; PLASMA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT FAILURE; VIRUS LOAD; VIRUS REPLICATION;

ADENINE; DIDEOXYNUCLEOSIDES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MUTATION; PHOSPHONIC ACIDS; PILOT PROJECTS; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; RNA-DIRECTED DNA POLYMERASE; SEQUENCE ANALYSIS, PROTEIN; TREATMENT FAILURE; VIRAL LOAD;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 22544472176     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.79.15.9572-9578.2005     Document Type: Article

References (29)

1. Amiel, C., A. Kara, V. Schneider, G. Pialoux, W. Rozembaum, and J. C. Nicolas. 2004. The K65R mutation in tenofovir-naïve patients: frequent association with Q151M mutation, abstr. 627. In Abstracts of the 11th Conference on Retroviruses and Opportunistic Infections. Foundation for Retrovirology and Human Health, Alexandria, Va.
2. Deval, J., K. L. White, M. D. Miller, N. T. Parkin, J. Courcambeck, P. Halfon, B. Selmi, J. Boretto, and B. Canard. 2004. Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations. J. Biol. Chem. 279:509-516.
3. Fang, G., G. Zhu, H. Burger, J. S. Keithly, and B. Weiser. 1998. Minimizing DNA recombination during long RT-PCR. J. Virol. Methods 76:139-148.
4. Farthing, C., H. Khanlou, and V. Yeh. 2003. Early virologic failure in a pilot study evaluating the efficacy of abacavir, lamivudine and tenofovir in the treatment naïve HIV-infected patients, abstr. 43. In Antiviral Therapy, 2003, vol. 8, suppl. 1. International Medical Press, London, United Kingdom.
5. Gallant, J. E., A. E. Rodriguez, W. Weinberg, B. Young, D. Berger, M. L. Lim, Q. Liao, L. Ross, J. Johnson, and M. S. Shaefer. 2003. Early non-response to tenofovir DF (TDF) + abacavir (ABC) and lamivudine (3TC) in a randomized trial compared to efavirenz (EFV) + ABC and 3TC: ESS30009 unplanned interim analysis, abstr. H-1722a. In Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
6. Gallant, J. E., S. Staszewski, A. L. Pozniak, E. DeJesus, J. M. Suleiman, M. D. Miller, D. F. Coakley, B. Lu, J. J. Toole, and A. K. Cheng. 2004. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 292:191-201.
7. Garcia-Lerma, J. G., P. J. Gerrish, A. C. Wright, S. H. Qari, and W. Heneine. 2000. Evidence of a role for the Q151L mutation and the viral background in development of multiple dideoxynucleoside-resistant human immunodeficiency virus type 1. J. Virol. 74:9339-9346.
8. Gu, Z., Q. Gao, H. Fang, H. Salomon, M. A. Parniak, E. Goldberg, J. Cameron, and M. A. Wainberg. 1994. Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2′,3′-dideoxycytidine and 2′,3′- dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 38:275-281.
9. Gulick, R. M., H. J. Ribaudo, C. M. Shikuma, S. Lustgarten, K. E. Squires, W. A. Meyer III, E. P. Acosta, B. R. Schackman, C. D. Pilcher, R. L. Murphy, W. E. Maher, M. D. Witt, R. C. Reichman, S. Snyder, K. L. Klingman, and D. R. Kuritzkes. 2004. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N. Engl. J. Med. 350:1850-1861.
10. Hance, A. J., V. Lemiale, J. Izopet, D. Lecossier, V. Joly, P. Massip, F. Mammano, D. Descamps, F. Brun-Vézinet, and F. Clavel. 2001. Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy. J. Virol. 75:6410-6417.
11. Jemsek, J., P. Hutcherson, and E. Harper. 2004. Poor virologic responses and early emergence of resistance in treatment naive, HIV-infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine, and tenofovir DF, abstr. 51. In Abstracts of the 11th Conference on Retroviruses and Opportunistic Infections. Foundation for Retrovirology and Human Health, Alexandria, Va.
12. Judo, M. S., A. B. Wedel, and C. Wilson. 1998. Stimulation and suppression of PCR-mediated recombination. Nucleic Acids Res. 26:1819-1825.
13. Julias, J. G., P. L. Boyer, M. J. McWilliams, W. G. Alvord, and S. H. Hughes. 2004. Mutations at position 184 of human immunodeficiency virus type-1 reverse transcriptase affect virus titer and viral DNA synthesis. Virology 322:13-21.
14. Kwok, S., D. E. Kellogg, N. McKinney, D. Spasic, L. Goda, C. Levenson, and J. J. Sninsky. 1990. Effects of primer-template mismatches on the polymerase chain reaction: human immunodeficiency virus type 1 model studies. Nucleic Acids Res. 18:999-1005.
15. Landman, R., D. Descamps, A. Trylesinski, A., Benalycherif, P. M. Girard, P. Yeni, M. Bentata, C. Michelet, P. Detruchis, B. Bonnet, C. Katlama, G. Peytavin, N. Margot, M. Miller, and F. Brun-Vezinet. 2005. Successful rescue therapy in patients developing K65R on tenofovir containing regimens: long term follow-up, abstr. 710. In Abstracts of the 12th Conference on Retroviruses and Opportunistic Infections. Foundation for Retrovirology and Human Health, Alexandria, Va.
16. Landman, R., G. Peytavin, D. Descamps, F. Brun-Vézinet, and the Tonus Study Group. 2004. Low genetic barrier to resistance is a possible cause of early virologic failures in once-daily regimen of abacavir, lamivudine and tenofovir: the Tonus Study. In Abstracts of the 11th Conference on Retroviruses and Opportunistic Infections. Foundation for Retrovirology and Human Health, Alexandria, Va.
17. McColl, D. J., N. A. Margot, M. Wulfsohn, D. F. Coakley, A. K. Cheng, and M. D. Miller. 2004. Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing intensification therapy with tenofovir disoproxil fumarate. J. Acquir. Immune Defic. Syndr. 37:1340-1350.
18. Parikh, U., D. Koontz, J. Hammond, L. Bacheler, R. Schinazi, P. Meyer, W. Scott, and J. W. Mellors. 2003. K65R: a multi-nucleoside resistance mutation of low but increasing frequency, abstr. 136. In Antiviral Therapy, 2003, Vol. 8, issue 3. International Medical Press, London, United Kingdom.
19. Pasquier, C., N. Millot, R. Njouom, K. Sandres, M. Cazabat, J. Puel, and J. Izopet. 2001. HIV-1 subtyping using phylogenetic analysis of pol gene sequences. J. Virol. Methods 94:45-54.
20. Roge, B. T., T. L. Katzenstein, N. Obel, H. Nielsen, O. Kirk, C. Pedersen, L. Mathiesen, J. Lundgren, and J. Gerstoft. 2003. K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine. Antiviral Ther. 8:173-182.
21. Ross, L., P. Gerondelis, E. G. Rouse, M. L. Lim, Q. Liao, B. C. Wine, S. K. Griffith, M. H. St. Clair, M. S. Shaefer, A. E. Rodriguez, J. E. Gallant, and E. R. Lanier. 2004. Impact of HIV resistance mutations drug resistance and viral fitness on antiretroviral activity of tenofovir/abacavir/lamivudine in the ESS30009 study, abstr. 159. In Antiviral Therapy, 2004, vol. 9, issue 4. International Medical Press, London, United Kingdom.
22. Shah, F. S., K. A. Curr, M. E. Hamburgh, M. Parniak, H. Mitsuya, J. G. Arnez, and V. R. Prasad. 2000. Differential influence of nucleoside analog-resistance mutations K65R and L74V on the overall mutation rate and error specificity of human immunodeficiency virus type 1 reverse transcriptase. J. Biol. Chem. 275:27037-27044.
23. Thompson, J. D., D. G. Higgins T. J. Gibson. 1994. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 22:4673-4680.
24. Tisdale, M., T. Alnadaf, and D. Cousens. 1997. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob. Agents Chemother. 41:1094-1098.
25. Wainberg, M. A. 1997. Increased fidelity of drug-selected M184V mutated HIV-1 reverse transcriptase as the basis for the effectiveness of 3TC in HIV clinical trials. Leukemia 11(Suppl. 3):85-88.
26. Wainberg, M. A., W. C. Drosopoulos, H. Salomon, M. Hsu, G. Borkow, M. Parniak, Z. Gu, Q. Song, J. Manne, S. Islam, G. Castriota, and V. R. Prasad. 1996. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science 271:1282-1285.
27. Wainberg, M. A., M. D. Miller, Y. Quan, H. Salomon, A. S. Mulato, P. D. Lamy, N. A. Margot, K. E. Anton, and J. M. Cherrington. 1999. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antiviral Ther. 4:87-94.
28. White, K. L., N. A. Margot, T. Wrin, C. J. Petropoulos, M. D. Miller, and L. K. Naeger. 2002. Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity. Antimicrob. Agents Chemother. 46:3437-3446.
29. Zolopa, A., S. Y. Rhee, D. Shin, L. Hurley, W. J. Fessel, and R. W. Shafer. 2004. The association of the K65R with Q151M and the relationship to antiretroviral treatment: results from northern California clinic population, abstr, 83. In Antiviral Therapy, 2004, vol. 9, issue 4. International Medical Press, London, United Kingdom.